Innovative studies employ PET/CT radiomics combined with clinical features to predict treatment response in Hodgkin lymphoma patients. These methodologies, leveraging advanced imaging biomarkers and statistical modeling, provide improved stratification for therapy optimization. The integration of these predictive models into clinical workflows offers potential for personalized treatment plans and enhanced patient outcomes.